| Institution: | 1.Liver Unit,Clinica Universidad de Navarra, and Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBEREHD),Pamplona,Spain;2.Nuclear Medicine,IFO Regina Elena National Cancer Institute,Rome,Italy;3.General Surgery and Transplantation Unit,San Camillo Hospital,Rome,Italy;4.Interventional Radiology,Ospedale S.M.Goretti,Latina,Italy;5.Azienda Ospedaliero Universitaria di Bologna,Bologna,Italy;6.Diagnostic and Interventional Radiology,Azienda Ospedaliera S. M. della Misericordia,Udine,Italy;7.Nuclear Medicine,Universit?tsklinik Bonn,Bonn,Germany;8.Interventional Radiology,LMU Klinikum der Universit?t München,Munich,Germany;9.Onco Interventional Radiology,Istituto Tumori Pascale,Naples,Italy;10.Data Reduction LLC,Chester,USA;11.Interventional Radiology,Clinica Universidad de Navarra,Pamplona,Spain;12.Nuclear Medicine,Ospedale S.M.Goretti,Latina,Italy;13.Nuclear Medicine,Azienda Ospedaliera S. M. della Misericordia,Udine,Italy;14.Department of Radiology,University of Bonn,Bonn,Germany;15.Hepatobiliary Surgery,Istituto Tumori Pascale,Naples,Italy;16.Medical Oncology,S. Orsola-Malpighi Hospital,Bologna,Italy;17.Interventional Radiology,IFO Regina Elena National Cancer Institute,Rome,Italy;18.Nuclear Medicine,Istituto Tumori Pascale,Naples,Italy |
| Abstract: | PurposeRadioembolisation is part of the multimodal treatment of hepatocellular carcinoma (HCC) at specialist liver centres. This study analysed the impact of prior treatment on tolerability and survival following radioembolisation.MethodsThis was a retrospective analysis of 325 consecutive patients with a confirmed diagnosis of HCC, who received radioembolisation with yttrium-90 resin microspheres at eight European centres between September 2003 and December 2009. The decision to treat was based on the clinical judgement of multidisciplinary teams. Patients were followed from the date of radioembolisation to last contact or death and the nature and severity of all adverse events (AEs) recorded from medical records.ResultsMost radioembolisation candidates were Child-Pugh class A (82.5%) with multinodular HCC (75.9%) invading both lobes (53.1%); 56.3% were advanced stage. Radioembolisation was used first-line in 57.5% of patients and second-line in 34.2%. Common prior procedures were transarterial (chemo)embolisation therapies (27.1%), surgical resection/transplantation (17.2%) and ablation (8.6%). There was no difference in AE incidence and severity between prior treatment subgroups. Median (95% confidence interval CI]) survival following radioembolisation was similar between procedure-naive and prior treatment groups for Barcelona Clinic Liver Cancer (BCLC) stage A: 22.1 months (15.1–45.9) versus 30.9 months (19.6–46.8); p?= 0.243); stage B: 18.4 months (11.2–19.4) versus 22.8 months (10.9–34.2); p?= 0.815; and stage C: 8.8 months (7.1–10.8) versus 10.8 months (7.7–12.6); p?= 0.976.ConclusionsRadioembolisation is a valuable treatment option for patients who relapse following surgical, ablative or vascular procedures and remain suitable candidates for this treatment. |
